RESUMO
Objective@#To observe the clinical efficacy and safety of Q-modulated laser combined with compound repair of oligosaccharides in the treatment of melasma.@*Methods@#From January 2017 to December 2018, 90 patients with chloasma were divided into Q-switched laser treatment group (control group) and Q-switched laser combined repair oligopeptide treatment group (experimental group) according to random number table method. In the experimental group, the interval between microneedle introduction of oligopeptide and Q-switched laser therapy was 2 weeks, and the treatment was carried out alternately. Each treatment lasted for 4 months, with a total of 8 treatments completed. The control group was treated with Q-switched laser only. Each patient was treated four times, once a month for four months. All patients were evaluated before treatment and 1 month after treatment. Evaluation indicators: (1) Macular severity index (MASI), calculating its decline rate, analyzing the improvement of chloasma; (2) Applying Visia skin analyzer to evaluate the characteristic count of brown spots, calculating its decline rate; (3) Doctors Subjectively Evaluate Patient Pigmentation Legacy; (4) Patient self-evaluation. Measuring data were tested by t-test and counting data by Chi square test.@*Results@#All subjects completed the treatment. Most of the chloasma in the two groups improved significantly after treatment. In the control group, the MASI decreased by 75.61%, 1 case of inefficiency, 13 cases of improvement, 28 cases of marked improvement and 3 cases of recovery. In the experimental group, the MASI decreased by 85.25%, 0 cases of inefficiency, 6 cases of improvement, 27 cases of significant improvement and 12 cases of recovery. Comparing the improvement of the two groups, the experimental group was better than the control group, the difference was statistically significant (χ2=9.00, P=0.03). After treatment, the number of chloasma brown spots in the two groups improved significantly. In the control group, the decrease rate of chloasma brown spots was (1.59 ± 1.33)% and in the trial experiment was (3.45± 1.54)%. The experimental group was better than the control group, and the difference between the two groups was statistically significant (P=0.01). The overall evaluation of therapeutic effect by doctors showed that 95.56% (43/45) of the patients in the experimental group had clearance rate greater than 75%, which was better than 86.67% (39/45) of the control group. There was a significant difference between the two groups (P<0.05). The self-evaluation result showed that the improvement rate of the experimental group was 66.67% (30/45) which was more than 75%, which was better than 37.78% (17/45) of the control group. The difference was statistically significant (P=0.04).@*Conclusions@#Q-switched laser combined with compound repair oligopeptide can effectively treat chloasma with less adverse reactions.